Dr. Gomez has over twenty years of experience in the biopharmaceutical industry and has managed the development of 10 marketed drugs, mostly in the cardiovascular area. Dr. Gomez has previously served as President and CEO of Transcend Therapeutics, Inc., CEO of Zengen, Inc., Vice President of Medical Affairs for Vertex Pharmaceuticals and as an Executive Director with Ciba-Geigy Corporation. From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPrint™ genomics, Inc., PRB Pharmaceuticals, Inc. and Asia Healthcare Ltd. Dr. Gomez received an M.D. from the National University of Colombia, a Ph.D. from Marquette University, and a Diploma in Clinical Pharmacology from Tulane University.

Dr. Frudakis founded GAFF biologic, the predecessor in interest to DNAPrint™ genomics, Inc., in 1998. He served as its President and Chief Executive Officer. Prior to founding GAFF biologic, Dr. Frudakis was a research scientist for Corixa Corporation for four years. While at Corixa he developed several new techniques for RNA fingerprinting, managed and executed high-throughput gene discovery programs for various cancers and was instrumental in the company's early success in attracting research and development partners. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, Magna cum laude graduate of the University of California Irvine where he received a BS degree in Biological Sciences.  Dr. Frudakis also earned a doctorate degree in molecular and cell biology from the University of California Berkeley.

See Under Management

See Under Management